News

Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi, plans to expand the ongoing phase 2 studies evaluating experimental drug KT-474 in treating two skin conditions: hidradenitis suppurativa and atopic dermatitis.

Sanofi opted to expand the phase 2 studies of KT-474 to accelerate the advancement of the drug into pivotal testing. The French drugmaker's decision came on the heels of a positive preliminary review of KT-474's safety and efficacy data by an Independent Data Review Committee.

Why are investors excited about Kymera's news?

Anything that could potentially speed up the timeline for getting a product to market is great news for a clinical-stage biopharma company. Investors are justifiably thrilled with Sanofi's decision to expand phase 2 studies of KT-474.

The drug could have tremendous commercial potential if it does eventually win regulatory approval. Hidradenitis suppurativa is a chronic condition that causes painful lumps beneath the skin and represents an estimated $1 billion market. Atopic dermatitis is a chronic skin condition that represents an estimated $8 billion market. KT-474 could also target other autoimmune diseases.

Is Kymera Therapeutics stock a buy?

Risk-averse investors will probably want to stay on the sidelines with Kymera Therapeutics. There's no guarantee KT-474 will be successful in clinical studies and win approval. However, aggressive investors could consider this biotech stock. Kymera's market cap is only around $2.3 billion. If KT-474 is successful, the company might be worth a lot more within a few years.

Should you invest $1,000 in Kymera Therapeutics right now?

Before you buy stock in Kymera Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kymera Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $785,556!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of July 8, 2024

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Kymera Therapeutics. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.